MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in precl… Read more
MegaPro Biomedical Co., Ltd (6827) - Total Liabilities
Latest total liabilities as of June 2025: NT$29.45 Million TWD
Based on the latest financial reports, MegaPro Biomedical Co., Ltd (6827) has total liabilities worth NT$29.45 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MegaPro Biomedical Co., Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how MegaPro Biomedical Co., Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MegaPro Biomedical Co., Ltd Competitors by Total Liabilities
The table below lists competitors of MegaPro Biomedical Co., Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tinybuild Inc
LSE:TBLD
|
UK | GBX8.33 Million |
|
Zovio Inc
PINK:ZVOI
|
USA | $55.55 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down MegaPro Biomedical Co., Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MegaPro Biomedical Co., Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MegaPro Biomedical Co., Ltd (2020–2024)
The table below shows the annual total liabilities of MegaPro Biomedical Co., Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$19.96 Million | -21.73% |
| 2023-12-31 | NT$25.51 Million | -9.98% |
| 2022-12-31 | NT$28.34 Million | +5.85% |
| 2021-12-31 | NT$26.77 Million | +42.57% |
| 2020-12-31 | NT$18.77 Million | -- |